<div id="readability-page-1"><div><p><span></span></p><ul><li><span>Novo Nordisk has released the first GLP-1 pill for obesity, strengthening its role in the growing oral weight-loss drug market as competitors develop similar treatments.</span><span>1</span></li><li><span>Novo Nordisk may face competition for its GLP-1 drugs, Ozempic and Wegovy, as generics of semaglutide could be produced for under $3 monthly, impacting costs significantly.</span><span>2</span></li><li><span>Novo Nordisk has resolved its legal dispute with Hims &amp; Hers Health, forming a partnership to sell its weight-loss drugs on Hims' platform, with an announcement expected soon.</span><span>3</span></li></ul></div></div>

HIMS

HIMZ

<p>Novo Nordisk has launched the first GLP-1 pill for obesity, enhancing its position in the oral weight-loss drug market. However, it may face competition from generics of its GLP-1 drugs, Ozempic and Wegovy, which could be produced at significantly lower costs. Additionally, Novo Nordisk has settled its legal dispute with Hims & Hers Health and is set to partner with them to sell its weight-loss drugs on their platform, with an announcement forthcoming.</p>

TradingView

Hims & Hers Health

SPDR S&P Health

Defiance Daily Target 2X Long HIMS ETF

Defiance Daily Target 2X Long NVO ETF

SPDR S&P Biotech

iShares Global Healthcare

Defiance Leveraged Long +Income HIMS ETF

iShares US Pharma

ALPS Medical Breakthrough

iShares Biotechnology ETF

SPDR S&P Health Equip

VanEck Biotech ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Novo Nordisk AS

iShares US Healthcare Providers

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Medical Devices

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Key facts: Novo Nordisk launches GLP-1 pill; faces generics competition; partners with Hims